REVIEW article
Front. Psychiatry
Sec. Behavioral and Psychiatric Genetics
Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1671122
This article is part of the Research TopicInsights in Behavioral and Psychiatric GeneticsView all 8 articles
The Clinical Use of Epigenetics in Psychiatry: A Narrative Review of Epigenetic Mechanisms, Key Candidate Genes, and Precision Psychiatry
Provisionally accepted
- 1Weill Cornell Medicine Department of Physiology and Biophysics, New York, United States
- 2Brain Health, Exeter, NH, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The etiology of psychiatric disorders is complex, involving both genetic and environmental factors with emerging evidence suggesting that epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, significantly contribute to mental health. The epigenome influences the development of psychiatric disorders and human behavior and may be considered in clinical observations. Epigenetic changes have been well-established in BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2, genes associated with psychiatric disorders, including schizophrenia, major depressive disorder (MDD), bipolar disorder (BP), post-traumatic stress disorder (PTSD), and autism spectrum disorder (ASD). Therefore, these epigenetic marks have the potential to be suitable biomarkers for diagnostics, as predictors of prognosis, and for the development of personalized treatments. By exploring the role of clinically relevant epigenetic genes, we review the role of the epigenome in the context of psychiatric disorders and human behavior; and we consider that these changes may be observed in the context of precision psychiatry. This review synthesizes findings from over 100 original research articles and reviews spanning a range of clinical studies. Despite promising associations, challenges in the onset of precision psychiatry, such as tissue heterogeneity, small sample sizes, and lack of replication, are likely to limit translation into clinical practice. Future research in precision psychiatry will help identify clinically actionable epigenetic biomarkers, ushering in an era of genomic medicine in psychiatry.
Keywords: precision psychiatry, epigenetics, Genomics, personalized medicine, psychiatric disorders
Received: 22 Jul 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Hayes, Mason and Miller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rachel Montel Hayes, contact@rachelmontelphd.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.